论文部分内容阅读
基于树突状细胞的治疗,在临床人类恶性肿瘤中已成为现实,而在人类自身免疫性疾病治疗时上,尽管在前期动物研究中获得压倒性支持已有二十年,但一些概念上问题的考虑阻碍了其在自身免疫性疾病治疗上的应用。1型糖尿病是研究得最好的自身免疫性疾病,而且其潜在免疫机制的了解得比较透彻,所以我们这里主要概述基于树突状细胞的治疗在1型糖尿病中应用的发展。这篇文章还强调了作者关于致耐受性树突状细胞的首度I期临床研究数据,期望推动其他类型的基于树突状细胞治疗手段,应用于一个或更多精心选择的1型糖尿病人群。
Dendritic cell-based therapies have become a reality in clinical human malignancies, and while the treatment of human autoimmune diseases has been overwhelmingly supported for more than two decades in previous animal studies, some conceptual problems The consideration has hindered its application in the treatment of autoimmune diseases. Type 1 diabetes is the best studied autoimmune disease and its underlying immunologic mechanisms are well understood, so here we outline briefly the use of dendritic cell-based therapies for type 1 diabetes. The article also highlights the authors’ first-phase, phase I clinical data on tolerogenic dendritic cells in hopes of driving other types of dendritic-cell-based therapies for one or more well-chosen type 1 diabetes crowd.